Skip to contentHome page Seeking Alpha - Power to InvestorsJan. 01, 2026 7:14 AM ETXencor, Inc. (XNCR) StockMyriam Alvarez3.11K FollowersCommentsXNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties.This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed.XNCR’s lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally.Management also believes that RCC spending is concentrated in a few branded therapies. This could prove an interesting opportunity for their platform.Thus, I feel XNCR offers compelling upside potential with its drug candidates for long-term investors, despite its inherent early-stage and partner risks.adventtr/E+ via Getty ImagesXencor, Inc. (XNCR) is a clinical-stage antibody engineering company. XNCR advances a wholly owned pipeline while also monetizing its technology through partnerships that can generate upfront payments, milestones, and royalties. Its internal pipeline includes XmAb942 in inflammatory bowelThis article was written byMyriam Alvarez3.11K FollowersMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking Alpha. Our analyses are conducted independently, and we adhere to Seeking Alpha's Shared Association Guidelines.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.